Claros Mortgage Trust Inc (CMTG)

Nov 5, 2026

Karyopharm Therapeutics (NASDAQ:KPTI) has filed for Chapter 11 bankruptcy with a $110 million superpriority debtor-in-possession loan, expecting its current equity to become worthless. Meanwhile, Medical Properties Trust (NYSE:MPT), Claros Mortgage Trust (NYSE:CMTG), and SelectQuote (NYSE:SLQT) are struggling, with MPT showing softer core funds from operations despite reported profits, CMTG posting a net loss and significant credit loss reserves, and SLQT facing a reverse stock split vote to maintain NYSE compliance. The article highlights the precarious positions of these "penny stocks" and the uncertain future for their shareholders.

Nov 4, 2026

Claros Mortgage Trust (NYSE:CMTG) reported a Q3 2026 GAAP net loss of USD 14.3 million and a distributable loss of USD 12.1 million, yet its stock rallied 68.71% to USD 1.87, approximately 22% of its book value. The company's leverage ratio improved, with net debt to equity falling to 1.7x, but the significant price jump is unconfirmed and could be influenced by its penny stock status. Investors are advised to monitor loan sales and watchlist resolutions, as the Q3 loss leaves the dividend decision open.

Nov 3, 2026

Claros Mortgage Trust (NYSE:CMTG) announced its quarterly earnings, reporting a loss of $0.08 per share, significantly beating analyst estimates of a $0.39 loss. The company's revenue of $32.64 million also surpassed the consensus estimate of $24.25 million. Despite beating expectations, analyst sentiment remains broadly negative with a "Strong Sell" consensus and a $2.08 average price target, while company insiders have recently purchased shares.